Eradication of Helicobacter pylori: Past, present and future

Helicobacter pylori is the major cause of chronic gastritis and peptic ulcers. Since the classification as a group 1 carcinogenic by International Agency for Research on Cancer, the importance of the complete H. pylori eradication has obtained a novel meaning. Hence, several studies have been made i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2014-09, Vol.189, p.169-186
Main Authors: Lopes, Daniela, Nunes, Cláudia, Martins, M Cristina L, Sarmento, Bruno, Reis, Salette
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Drug Delivery Systems
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Nanoparticles - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Helicobacter pylori is the major cause of chronic gastritis and peptic ulcers. Since the classification as a group 1 carcinogenic by International Agency for Research on Cancer, the importance of the complete H. pylori eradication has obtained a novel meaning. Hence, several studies have been made in order to deepen the knowledge in therapy strategies. However, the current therapy presents unsatisfactory eradication rates due to the lack of therapeutic compliance, antibiotic resistance, the degradation of antibiotics at gastric pH and their insufficient residence time in the stomach. Novel approaches have been made in order to overcome these limitations. The purpose of this review is to provide an overview about the current therapy and its limitations, while highlighting the possibility of using micro- and nanotechnology to develop gastric drug delivery systems, overcoming these difficulties in the future.
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2014.06.020